Mankind Pharma share price jumps over 8% on robust Q1 results
1 year, 4 months ago

Mankind Pharma share price jumps over 8% on robust Q1 results

Live Mint  

Mankind Pharma share news: Mankind Pharma share price jumped over 8% on Thursday's trade after pharmaceutical company reported strong Q1FY24 numbers on Wednesday. Mankind Pharma share price opened at ₹1,890 apiece on BSE, and Mankind Pharma stock price was hovering near its 52-week high level. Mankind pharma Q1 results posted record quarter in all aspects. We have On the technical front, Mankind Pharma stock price fell 4.1% underperformed its sector by 0.8% in the past week, as per trendlyne data.

Pharma Mankind Pharma Q1 Results Mankind  share  grew  mankind  strong  jumps  growth  ebitda  robust  price  q1  results  pharma  crore

History of this topic

Mankind Pharma pledges 39.68% stake in Bharat Serums to secure ₹5,000 crore NCDs
1 month, 1 week ago

Mankind Pharma pledges 39.68% stake in Bharat Serums to secure ₹5,000 crore NCDs

Live Mint  

Stocks to watch: Mankind Pharma Limited has pledged 39.68 per cent of its equity stake in its fully-owned subsidiary Bharat Serums and Vaccines Limited to secure non-convertible debentures totalling ₹5,000 crores. Mankind Pharma's share price closed in green, up 2.68 per cent, at ₹2,600.00 on November 15 on BSE. Mankind Pharma, in an exchange filing, announced, “This is to inform …

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY
1 month, 1 week ago

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

Live Mint  

Suven Pharmaceuticals Q2 Results Live : Suven Pharmaceuticals declared their Q2 results on 12 Nov, 2024, showcasing a robust performance with a topline increase of 11.54% year-over-year. In comparison to the previous quarter, Suven Pharmaceuticals reported an impressive revenue growth of 11.72% along with a significant profit increase of 35.28%. As of 13 Nov, 2024, all analysts covering the company …

Natco Pharma Q2 Results Live: Profit Rises by 83.55% YoY
1 month, 1 week ago

Natco Pharma Q2 Results Live: Profit Rises by 83.55% YoY

Live Mint  

Natco Pharma Q2 Results Live : Natco Pharma announced its Q2 results on November 12, 2024, revealing a significant growth in both topline and profit. In terms of stock performance, Natco Pharma experienced a -2.19% return over the past week; however, the company has delivered a robust 40.5% return in the last six months and an impressive 71.42% year-to-date return. …

Gland Pharma Q2 net declines 16% to ₹163.5 cr.
1 month, 2 weeks ago

Gland Pharma Q2 net declines 16% to ₹163.5 cr.

The Hindu  

Generic injectable-focused Gland Pharma consolidated net profit declined almost 16% to ₹163.5 crore for the quarter ended September compared to the ₹194 crore in the year earlier period. The lower net profit came on a more than 2% increase in the revenue from operations at ₹1,405.8 crore. Looking ahead, we remain focused on our strategic priorities, which include entering new …

IT and pharma stocks nudge Indian shares higher
3 months, 1 week ago

IT and pharma stocks nudge Indian shares higher

Hindustan Times  

By Bharath Rajeswaran IT and pharma stocks nudge Indian shares higher BENGALURU -Indian shares recovered from a lacklustre start to end higher on Tuesday, with IT and pharma stocks leading the charge ahead of crucial U.S. inflation data that could pave the way for interest rate cuts. "A softer-than-expected U.S. inflation data could boost the chances of a 50 basis …

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys
4 months, 3 weeks ago

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys

Live Mint  

Ambuja Cements: The company reported a consolidated profit of ₹646.31 crore for Q1FY25, a 28.6% YoY decline due to rising expenses and lower revenues. Tata Steel: The company reported a 51% jump in consolidated net profit to ₹960 crore for Q1FY25, up from ₹634 crore YoY, but missed analysts’ expectations of ₹1,025 crore. Redington: The company reported a 15% YoY …

Mankind pharma share price opens 4.6% higher as is set to buy 100% stake in Bharat Serum and Vaccines
4 months, 4 weeks ago

Mankind pharma share price opens 4.6% higher as is set to buy 100% stake in Bharat Serum and Vaccines

Live Mint  

Stock Market Today: Mankind Pharma share price opened 4.6% higher post to its announcements pertaining to acquisition of stakes in Bharat Serums and Vaccines Limited. Mankind Pharma announced having entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Limited from Advent International, one of the key private equity investors. Deal valuation Mankind Pharma said …

Mankind Pharma promoters to offload shares to meet minimum shareholding norms
10 months, 2 weeks ago

Mankind Pharma promoters to offload shares to meet minimum shareholding norms

Live Mint  

Mankind Pharma's promoters, on Wednesday, revealed their plans to reduce their shareholding between February 8 and February 15, to meet the minimum public shareholding requirements. Sheetal Arora intends to divest 0.45 percent of her shares, totaling 18.17 lakh shares, while Arjun Juneja plans to sell 0.6 percent, equivalent to 24.01 lakh shares. Puja Juneja is also set to sell 22.7 …

Mankind share price dips more than 1%. Analysts positive on domestic prospects
1 year, 1 month ago

Mankind share price dips more than 1%. Analysts positive on domestic prospects

Live Mint  

Share Price of Mankind Pharma Ltd dipped more than 1% in the intraday trades on Friday. Mankind Pharma felt the impact of softness in acute segment sales during the September quarter that pulled down the domestic growth even as overall performance was lifted by continued traction in the Chronic portfolio, some price hikes and higher exports as per analysts. As …

Sun Pharma shares rise as Q2 results surpass street estimates
1 year, 1 month ago

Sun Pharma shares rise as Q2 results surpass street estimates

Live Mint  

Sun Pharma share price was trading in green on Thursday's session after the company's Q2 results surpassed street's estimation both on the profit and revenue front on Wednesday. Brokerages have therefore maintained their "buy" rating for the stock and revised their target price for Sun Pharma shares. Kotak Institutional Equities Brokerage refers to Sun Pharma Q2 results as a well-rounded …

Panacea Biotec shares fall 3% after Baddi unit gets 9 observations from US FDA
1 year, 2 months ago

Panacea Biotec shares fall 3% after Baddi unit gets 9 observations from US FDA

Live Mint  

Panacea Biotec share price fell over 3% on Friday's trading session after United States Food and Drug Administration issued form 483 with nine observations for Baddi Unit on Thursday. Panacea Biotec stock price witnessed a a gap down opening in today's session however prices have smartly recovered from intraday lows in the first hour. " The USFDA, an American drug …

Mankind Pharma Q1 results: Profit soars 66% on strong sales
1 year, 4 months ago

Mankind Pharma Q1 results: Profit soars 66% on strong sales

Live Mint  

Mankind Pharma Ltd on Wednesday reported a 66% growth in profit for the first quarter of fiscal year 2024 on strong domestic sales. The company's total income rose to ₹2,637 crore in June quarter of the current fiscal from ₹2,196 crore in the year-ago period, Mankind Pharma said in an exchange filing. “The pharma segment outperformed the Indian pharma market …

Q1 results preview: Here’s why pharma companies are expected to show improvement
1 year, 5 months ago

Q1 results preview: Here’s why pharma companies are expected to show improvement

Live Mint  

The domestic brokerage Nuvama Institutional Equities anticipates better results from the pharmaceutical companies in Q1FY24. Additionally, the brokerage claimed that gRevlimid boosts at Dr. Reddy's Laboratories Ltd, Zydus Lifesciences Ltd, Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Natco Pharma will help to maintain US stability. Aurobindo Pharma: The brokerage anticipated in its analysis that new product launches and increased market …

Mankind Pharma Q4 results: PAT zooms 52% YoY to ₹294 Cr, revenue up 19%
1 year, 6 months ago

Mankind Pharma Q4 results: PAT zooms 52% YoY to ₹294 Cr, revenue up 19%

Live Mint  

The fourth-largest pharmaceutical company in India, Mankind Pharma, today disclosed its financial results for the fourth quarter and full year ended March 31, 2023. Mankind Pharma said its net profit for the quarter under review reached ₹294 Cr up by 52% YoY from ₹193 Cr in the corresponding quarter of the previous fiscal year. Mankind Pharma said its revenue from …

Gland Pharma Q4 net profit declines 72% year-on-year
1 year, 7 months ago

Gland Pharma Q4 net profit declines 72% year-on-year

Live Mint  

The generic injectable focused pharmaceutical company, Gland Pharma Ltd’s reported net profits at ₹78.68 Crore during Q4, saw a sharp decline of 72% over ₹285.90 Crore reported in the year-ago quarter. The India market that accounted for 8% of total revenues during Q4FY23 and witnessed a 68% year-on-year decline is sales which the company attributed to higher base of COVID …

I-T Department raids Mankind Pharma premises over tax evasion allegations; company says extending full cooperation
1 year, 7 months ago

I-T Department raids Mankind Pharma premises over tax evasion allegations; company says extending full cooperation

The Hindu  

“The Income Tax Department on May 11 conducted raids on the premises of Mankind Pharma over allegations of tax evasion,” official sources said. In a BSE filing, Mankind Pharma said it was extending "full cooperation" to the Department. The officials of the company and its subsidiaries are cooperating with the officials of the Income Tax Department and are responding to …

Mankind Pharma IPO: Issue subscribed 14% on Day 1; NIIs steal the show
1 year, 7 months ago

Mankind Pharma IPO: Issue subscribed 14% on Day 1; NIIs steal the show

Live Mint  

Mankind Pharma's initial public offer was subscribed 14% on Day 1. The issue received response from non-institutional investors who subscribed about 33%, retail investors who had subscribed about 10% and qualified institutional investors subscribed 8% of the allotted quota to them. The non-institutional investors' portion received bids for 19,95,968 shares against 60,08,827 on offer for this segment. The retail investors' …

Mankind Pharma IPO: GMP, subscription status, review, other details. Buy or not?
1 year, 7 months ago

Mankind Pharma IPO: GMP, subscription status, review, other details. Buy or not?

Live Mint  

Mankind Pharma IPO is opening for subscription today and the public issue worth ₹4,326.36 crore will remain open for bidding till 27th April 2023. Here we list out important Mankind Pharma IPO details in 10 points: 1] Mankind Pharma IPO date: The public issue has opened today and it will remain open for bidding till 27th April 2023. 9] Mankind …

Mankind Pharma raises ₹1,298 cr from anchor investors ahead of IPO
1 year, 7 months ago

Mankind Pharma raises ₹1,298 cr from anchor investors ahead of IPO

Live Mint  

Mankind Pharma on Monday said it has raised ₹1,298 crore from anchor investors ahead of its initial share sale that opens for subscription on 25 April, 2023. “Trading Members of the Exchange are hereby informed that, under Anchor Investors portion in the Public Issue of Mankind Pharma Limited, 1,20,17,652 equity shares have been subscribed today at Rs. Canada Pension Plan …

Mankind Pharma IPO: From key dates to price band, all you need to know
1 year, 8 months ago

Mankind Pharma IPO: From key dates to price band, all you need to know

Live Mint  

Mankind Pharma Ltd's initial public offer will open for subscription on Tuesday, April 25, and close on Thursday, April 27. The company has fixed the price band at Rs 1,026 to Rs 1,080 per equity share for the proposed initial public offer. The OFS comprises about 37.1 lakh shares by Ramesh Juneja, 35.1 lakh shares by Rajeev Juneja, 28 lakh …

Pharma stock may rally over 27% as brokerage sees upside
2 years, 6 months ago

Pharma stock may rally over 27% as brokerage sees upside

Live Mint  

Gland Pharma remains on track to deliver growth, but at the same time, it continues to be vigilant about not being over dependent on a specific geography, said brokerage Nirmal Bang in a note as it hosted the Gland Pharma management at its Annual Investor Conference to discuss the company’s business outlook. The brokerage house has a Buy rating on …

Discover Related